PLT Health Solutions Release Water-Soluble Joint Supplement: AquaLOX
31 Mar 2016 --- PLT Health Solutions, Inc. has announced a water-soluble version of their best-selling 5-LOXIN for joint health support, AquaLOX.
The new ingredient AquaLOX is a potent Boswellia serrata extract, documented to have a similar pharmacokinetic profile to 5-LOXIN – which has been clinically demonstrated to improve joint comfort and protect against cartilage degradation.
In addition to being water-soluble, PLT Health Solutions states that AquaLOX “represents a major breakthrough with its pleasant taste profile, allowing – for the first time – the use of Boswellia serrata extract for taste-sensitive formulations such as chews, gummies, stick-packs, shots and more.” The technology used to manufacture this water-soluble version of Boswellia serrata has been more than five years in development.
According to Seth Flowerman, Executive Vice President at PLT Health Solutions, the development of AquaLOX was driven by a market looking to bring the efficacy, clinical support, and brand recognition of 5-LOXIN to a broad new range of product types:
“5-LOXIN is a market leading joint-health ingredient, available in well over a hundred consumer products on the market today. In a market that demands convenience and novel delivery systems, all Boswellia extracts were limited because of the challenging taste profile and lack of solubility – and the technology needed to achieve this was tricky.”
“With AquaLOX, we are finally able to deliver on our customers’ wish list and extend the 5-LOXIN franchise to a whole new range of products,” he said.
Clinically-studied support for joint comfort and mobility
In a recent human study, 5-LOXIN daily provided improvement in joint comfort and mobility within 7 days. Daily consumption provided significant benefits in WOMAC, VAS and LFI standardized testing methodologies for joint health 5-LOXIN was also shown to significantly inhibit matrix metalloproteinase (MMP-3), enzymes that break down cartilage, and connective tissues.
In a recent human study, 5-LOXIN daily provided improvement in joint comfort and mobility within 7 days. Daily consumption provided significant benefits in WOMAC, VAS and LFI standardized testing methodologies for joint health 5-LOXIN was also shown to significantly inhibit matrix metalloproteinase (MMP-3), enzymes that break down cartilage, and connective tissues.
5-LOXIN inhibits an enzyme called 5-lipoxygenase. 5-LOX inhibitors follow a distinctly different pathway than COX-2 inhibitors, and while both are involved in the breakdown of arachidonic acid, 5-LOX inhibitors do not exhibit the potentially negative effects that have been associated with COX-2 inhibitors.
5-LOXIN is a selective, non-redox 5-LOX inhibitor, which means that its action is very targeted. Safety for 5-LOXIN is supported by historic usage, published human studies, and extensive safety and toxicity studies.
All content and features on this website are copyrighted with all rights reserved. The full details can be found in our privacy statement
